Van Lanschot Kempen Investment Management N.V. Has $16.62 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Van Lanschot Kempen Investment Management N.V. cut its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,564 shares of the medical research company's stock after selling 73,191 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Edwards Lifesciences were worth $16,624,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Abacus Planning Group Inc. raised its position in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after purchasing an additional 140 shares during the period. Bowman & Co S.C. grew its stake in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock valued at $924,000 after buying an additional 148 shares in the last quarter. Moors & Cabot Inc. raised its holdings in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock valued at $4,041,000 after buying an additional 152 shares during the period. Quadrant Capital Group LLC lifted its position in Edwards Lifesciences by 3.1% during the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after acquiring an additional 156 shares in the last quarter. Finally, Pegasus Asset Management Inc. boosted its holdings in Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after acquiring an additional 159 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $73.00 to $80.00 in a research report on Thursday. Robert W. Baird raised their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday. Finally, Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Performance

EW traded up $0.93 during trading hours on Friday, hitting $76.06. The company's stock had a trading volume of 6,330,152 shares, compared to its average volume of 4,987,541. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a 50-day simple moving average of $70.93 and a 200 day simple moving average of $71.02. The firm has a market capitalization of $44.71 billion, a PE ratio of 10.91, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same quarter in the prior year, the company posted $0.66 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company's stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock valued at $5,163,062 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.